Biotin is small compared with many fluorescent dyes, but its position and linker still affect peptide binding, solubility and access to streptavidin. A custom biotinylated peptide synthesis service should define the complete conjugate and prove that free biotin and unlabeled peptide have been controlled. “Biotinylated” alone is not a release specification.
Select a site that does not obstruct the assay
N-terminal biotinylation is straightforward when the native N-terminus is not required for binding. A lysine side chain can provide another attachment site, provided other amines are protected and the selected lysine is not part of the interaction motif. An added cysteine followed by selective conjugation is useful for some constructs but creates a different peptide.
State whether the label is direct or separated by an Ahx, PEG or other spacer. A linker can improve accessibility on streptavidin-coated surfaces, yet it also changes hydrophobicity, mass and effective distance from the peptide.
Lock the exact construct in the quotation
Write the biotin and linker into the controlled sequence notation. Specify termini, disulfides, salt form and any other modification. If both biotinylated and unlabeled controls are needed, require identical peptide sequence and terminal chemistry.
For competition assays, consider ordering the control and conjugate from the same synthesis campaign or at least under aligned specifications. Lot differences in salt and content can otherwise look like label effects.
Free biotin is an assay-active impurity
Residual free biotin can occupy streptavidin sites even at levels that appear minor by peptide-focused HPLC. The analytical method must detect it or use an orthogonal test. UV response differs between free biotin, peptide and conjugate, so area normalization at one wavelength may be misleading.
Ask how excess reagent is removed and how the final free-biotin limit is verified. Dialysis or desalting alone may be inadequate for a hydrophobic peptide or when recovery is poor.
Confirm identity and attachment position
LC-MS should show the complete conjugate mass and reveal relevant unlabeled or multi-labeled species. When several reactive residues exist, the expected mass does not prove correct position. Selective protection, tandem MS or peptide mapping may be needed.
Review the full spectrum, not only a typed mass result. Biotinylation can change charge-state distribution and chromatographic retention. The HPLC and MS data must correspond to the shipped lot.
Content and immobilization are separate questions
Gross lyophilized weight includes counterion, water and residual salts. Net peptide content or another quantitative assignment is necessary when surface loading or solution concentration matters. A high HPLC purity result is not a vial-content result.
The buyer should validate functional capture in the intended streptavidin format. Linker length, surface density and peptide orientation can alter apparent binding. Supplier QC confirms chemical material; it does not prove performance in every plate, bead or sensor system.
Packaging should minimize adsorption and moisture
Low microgram fills are vulnerable to static loss and adsorption. Request low-bind vials, sensible aliquots and a documented fill tolerance. If the product is delivered in solution, define solvent, concentration basis, homogeneity, preservative status and shipping temperature.
- Exact biotin site and linker identity.
- Limits for free biotin, unlabeled and multi-labeled peptide.
- HPLC method, integration and full LC-MS data.
- Position evidence when multiple sites are possible.
- Content basis, counterion, aliquots and storage.
Does every biotinylated peptide need a linker? No. The decision depends on whether direct attachment interferes with recognition or surface access. Provide the assay format, immobilization surface, target concentration and required controls before synthesis. A technically useful supplier will question an attachment site likely to compromise the measurement.